Browsing Tag
CDSCO
15 posts
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
NATCO Pharma (NSE: NATCOPHARM) launches cheapest semaglutide in India at Rs 1,290 on Day 1 of patent expiry
NATCO Pharma launches generic semaglutide in India at INR 1,290 on Day 1 of patent expiry. What it means for GLP-1 markets. Read the full analysis.
Bajaj Healthcare (NSE: BAJAJHCARE) Q3 FY26 earnings: API exports double, PAT up 34%
Bajaj Healthcare’s API exports doubled in Q3 FY26, driving 31% revenue growth. Find out what its CNS pipeline and CDMO ramp mean for future expansion.
VIVATRONIX and SpineX secure CDSCO approval for xStep device: Can India’s new neuromodulation era transform paralysis care?
India approves VIVATRONIX–SpineX xStep device for paralysis care—marking a major leap for noninvasive neuromodulation and India’s medtech future.
Wockhardt secures approval for Miqnaf: A breakthrough in pneumonia treatment
In a landmark decision addressing the global challenge of antibiotic resistance, the Indian drug regulator, Central Drugs Standard…
Shocking discovery! Counterfeit drugs implicated in Alkem Laboratories investigation—What you need to know
In a shocking turn of events, Alkem Laboratories has uncovered that counterfeit drugs have been implicated in an…
Torrent Pharmaceuticals denies counterfeit allegations around Shelcal 500
Torrent Pharmaceuticals Limited, one of India’s leading pharmaceutical companies, has strongly refuted claims surrounding the quality of its…
Zydus advances PCSK9 inhibitor with Phase I clinical study approval
Zydus, a global pharmaceutical company, has secured permission from CDSCO, India, to kickstart the Phase I clinical study…
BaroPace gets CDSCO approval for RelieveHFpEF-II clinical trial in India
BaroPace Inc., a medical technology company focused on developing pacemaker regulation techniques based on blood pressure, has been…
Bharat Parenterals gets license and authorization for Favipiravir oral suspension for Covid treatment
Bharat Parenterals said that it has secured the license and authorization from Drugs Controller General of India (DCGI)…